Weisell Jonna, Ohukainen Pauli, Näpänkangas Juha, Ohlmeier Steffen, Bergmann Ulrich, Peltonen Tuomas, Taskinen Panu, Ruskoaho Heikki, Rysä Jaana
School of Pharmacy, University of Eastern Finland, POB 1627, 70211, Kuopio, Finland.
Research Unit of Biomedicine, Computational Medicine, University of Oulu, Oulu, Finland.
BMC Cardiovasc Disord. 2019 Dec 19;19(1):306. doi: 10.1186/s12872-019-01294-2.
Calcific aortic valve disease (CAVD) is an atheroinflammatory process; finally it leads to progressive calcification of the valve. There is no effective pharmacological treatment for CAVD and many of the underlying molecular mechanisms remain unknown. We conducted a proteomic study to reveal novel factors associated with CAVD.
We compared aortic valves from patients undergoing valvular replacement surgery due to non-calcified aortic insufficiency (control group, n = 5) to a stenotic group (n = 7) using two-dimensional difference gel electrophoresis (2D-DIGE). Protein spots were identified with mass spectrometry. Western blot and immunohistochemistry were used to validate the results in a separate patient cohort and Ingenuity Pathway Analysis (IPA) was exploited to predict the regulatory network of CAVD.
We detected an upregulation of complement 9 (C9), serum amyloid P-component (APCS) and transgelin as well as downregulation of heat shock protein (HSP90), protein disulfide isomerase A3 (PDIA3), annexin A2 (ANXA2) and galectin-1 in patients with aortic valve stenosis. The decreased protein expression of HSP90 was confirmed with Western blot.
We describe here a novel data set of proteomic changes associated with CAVD, including downregulation of the pro-inflammatory cytosolic protein, HSP90.
钙化性主动脉瓣疾病(CAVD)是一种动脉粥样硬化炎症过程;最终会导致瓣膜进行性钙化。目前尚无针对CAVD的有效药物治疗方法,许多潜在的分子机制仍不清楚。我们进行了一项蛋白质组学研究,以揭示与CAVD相关的新因素。
我们使用二维差异凝胶电泳(2D-DIGE),将因非钙化性主动脉瓣关闭不全接受瓣膜置换手术的患者的主动脉瓣(对照组,n = 5)与狭窄组(n = 7)进行比较。通过质谱鉴定蛋白质斑点。使用蛋白质印迹法和免疫组织化学在另一组患者中验证结果,并利用 Ingenuity 通路分析(IPA)预测 CAVD 的调控网络。
我们检测到主动脉瓣狭窄患者中补体 9(C9)、血清淀粉样蛋白 P 成分(APCS)和转胶蛋白上调,以及热休克蛋白(HSP90)、蛋白质二硫键异构酶 A3(PDIA3)、膜联蛋白 A2(ANXA2)和半乳糖凝集素-1 下调。蛋白质印迹法证实了 HSP90 蛋白表达降低。
我们在此描述了一组与 CAVD 相关的蛋白质组学变化的新数据集,包括促炎细胞溶质蛋白 HSP90 的下调。